Trump Signs Executive Order to Expedite FDA Review of Psychedelic Therapies
** President Donald Trump has signed an executive order to expedite the FDA review process of psychedelic drugs, including ibogaine, to treat post-traumatic stress disorder and potentially other severe mental health conditions. This move is aimed at accelerating the development and approval of psychedelic therapies, which could make life-changing treatments more widely available to patients in need.
Read More